International Journal of Oncology

Aims & Scope

The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality.

The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research.

All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4.9
2024	4.50

Journal Rank

Year	Value
2024	3429

Journal Citation Indicator

Year	Value
2024	1890

SJR (SCImago Journal Rank)

Year	Value
2024	1.226

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	142

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

  Citation: 1016

  Authors: Volker

• Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)

  Citation: 381

  Authors: Masaru

• Triple‑negative breast cancer therapy: Current and future perspectives (Review)

  Citation: 374

  Authors: Kwang‑Ai, Charles

• Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)

  Citation: 315

  Authors: GEORGE MIHAI, DENISA, PETRAS, QIAN, OCTAVIAN TUDOREL, EMMANOUIL, CONCETTINA, DEMETRIOS A., MASSIMO, ARISTIDIS M.

• Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)

  Citation: 308

  Authors: Wararat, Somchai, Suradej

• Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review)

  Citation: 288

  Authors: ALESSANDRO, ANDREA, SALVATORE, GIUSEPPA, ANNAMARIA, DEMETRIO, CATERINA

• The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer

  Citation: 279

  Authors: SHU-WEI, YUE-MING

• The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

  Citation: 272

  Authors: Nan, Yuanyuan, Wenwen, Jianjie, Dan, Zeyi, Jian-an

• JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells

  Citation: 263

  Authors: RENG-YUN, YUANYUAN, ZHE, LONGQIANG, HAIPING, ZEYI, JUN, HONG-TAO

• Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer

  Citation: 255

  Authors:

---